期刊文献+

新型重组溶瘤痘苗病毒感染联合免疫效应细胞及免疫检查点阻断三联治疗胃癌的研究 被引量:2

Experimental Study on Treatment of Gastric Cancer with New Recombinant Oncolytic Vaccinia Virus Infection Combined with Immune Effective Cells and Immune Checkpoint Blocking
暂未订购
导出
摘要 目的探讨溶瘤病毒感染、免疫效应细胞补充及免疫检查点阻断三者联合策略在胃癌治疗中的意义。方法以既往实验获得的痘苗病毒为基础构建的携带T淋巴细胞趋化因子CXCL9基因和白细胞介素7(IL-7)基因的重组溶瘤痘苗病毒(VV-IL7-CXCL9)干预治疗裸鼠皮下种植瘤方式建立的胃癌荷瘤动物模型。实验建立重组溶瘤痘苗病毒瘤内注射+细胞毒性T淋巴细胞(CTL)+免疫检查点阻断剂(PD-1单抗)三联干预组、三种措施单独干预组、二联干预组及空白对照组。按照既定分组给药干预后采用肿瘤生长曲线法、肿瘤抑制率法及动物活体发光法检测肿瘤治疗效果并采取ELISA法检测各组动物血清及组织匀浆CXCL9和IL-7两分子浓度。结果动物模型治疗干预结果显示重组溶瘤痘病毒+细胞毒性T淋巴细胞(CTL)+免疫检查点阻断剂(PD-1单抗)三联干预组肿瘤生长明显减缓,显著慢于其他干预组及空白对照组。结论在胃癌动物模型干预实验中采用重组溶瘤痘病毒瘤内注射+细胞毒性T淋巴细胞(CTL)+免疫检查点阻断剂(PD-1单抗)三联干预的生物免疫治疗策略具有强烈的抑瘤作用。 Objective To explore the significance of the combined strategy of oncolytic virus infection,immune effector cell supplement,and immune checkpoint blocking in the treatment of gastric cancer.Methods A tumor-bearing nude mouse model of gastric cancer was treated with recombinant oncolytic vaccinia virus carrying the CXCL9 gene of T lymphocyte chemokine and IL-7gene(VV-IL7-CXCL9)obtained in previous experiments.We established a triple-intervention group of recombinant oncolytic vaccinia virus intratumoral injection+cytotoxic T lymphocyte(CTL)+immune checkpoint blocker(PD-1 monoclonal antibody),a single-intervention group of three measures,a dual-intervention group,and a blank control group.After the intervention,tumor-growth curve method,tumor-inhibition rate method,and bioluminescence method were used to detect the tumor treatment effect.ELISA was used to detect CXCL9 and IL-7 molecule concentration in the serum and tissue homogenate of animals in each group.Results The therapeutic results of animal models showed that the tumor growth in the triple-intervention group of recombinant oncolytic poxvirus+CTL+immune checkpoint blocker(PD-1 monoclonal antibody)was significantly slower than those in the other intervention and the blank control group.Conclusion The combination of recombinant oncolytic poxvirus intratumoral injection+CTL+immune checkpoint blocker(PD-1 monoclonal antibody)exert a strong antitumor effect in intervention experiments on gastric-cancer animal models.
作者 张林 侯艳红 吴凯 张静 ZHANG Lin;HOU Yanhong;WU Kai;ZHANG Jing(The Eighth Medical Center,PLA General Hospital,Beijing 100091,China)
出处 《肿瘤防治研究》 CAS 2024年第6期426-431,共6页 Cancer Research on Prevention and Treatment
基金 首都卫生发展科研专项基金(2011-5007-01)。
关键词 胃癌 溶瘤痘病毒 免疫效应细胞 免疫检查点阻断治疗 Gastric cancer Oncolytic poxvirus Immune effector cells Immune checkpoint blocking therapy
  • 相关文献

参考文献4

二级参考文献52

  • 1周生 毛宁 等.双特异性抗体对克隆化LAK细胞增强和细胞毒的增强效应[J].中华微生物免疫学杂志,1995,1(11):159-159.
  • 2Cohen SJ, Pinover WH, watson jc, Meropoi NJ. Pancreatic cancer. Curr Treat Options Oncol 2000; 1:375-386 [PMID: 12057145 DOh 10.1007/ s11864-000-00652].
  • 3Chao YJ, Sy ED, Hsu HP, Shan YS. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. BMC Surg 2014; 14:72 [PM1D:25258022 DOI: 10.1186/1471-2482-14-72].
  • 4Meoni G, Cecere FL, Lucherini E, Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents, J Geriatr Oncol 2013; 4:282-290 [PMID: 24070465 DOI: 10.1016/ j.jgo.2013.04.005].
  • 5de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 2014; 741:8-16 [PMID: 2508922 DOI: 10.1016/j.ejphar.2014.07.041].
  • 6Watanabe M, Hara F, Kiyoto S, Takahashi M, Takabatake D, Takashima S, Aogi K, Ohsumi S. [Clinical experience with gemcitabine treatment for metastatic breast cancer]. Gan To Kagaku Ryoho 2013; 40:1355-1359 [PMID: 24105058].
  • 7Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunapharmacol 2009; 9:900-909 [PMID: 19336265 DOI: 10.1016/j.infirnp.2009.03.015].
  • 8Green MR. Gemcitabine safety overview. Semin Onco11996; 25:32-35 [PMID: 8893879].
  • 9Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb) 2014; 6:9-26 [PMID: 24104563 DOI: 10.1039/c3ib40165k].
  • 10Liboiron BD, Mayer LD. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv 2014; 5: 149-171 [PMID: 24483194 DOI: 10.4155/tde.13.149].

共引文献49

同被引文献23

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部